ChinaSpecialistCareSpecialtiesCare optionsRecordsSourcesFree Initial Review
Menu
Home / Gastroenterology / Intestinal Microbiota Therapy
Gastroenterology patient guide · 肠道微生态治疗

Microbiota Therapy in China

Considering microbiota therapy in China? Start with the specific indication, treatment evidence and centre assessment. This guide helps you identify the relevant records, questions for the receiving team and the scope of an individual estimate before a visit is agreed. The centre must confirm eligibility and actual access for your case.

Check my case & budgetRecords & cost enquiry ↓
Chinese gastroenterologist explaining regulated microbiota therapy and recurrent C difficile to an international patient

Medical records & cost enquiry

Microbiota Therapy: assessment and cost questions

For Intestinal Microbiota Therapy, the budget depends on the proposed care and the hospital. A useful estimate needs to distinguish:

The receiving centre must confirm availability and eligibility. This enquiry does not guarantee treatment, trial enrolment or access to a medicine.

  • The indication and hospital eligibility review
  • The specific regulated pathway being considered
  • Screening, delivery and follow-up scope

Hospital medical fees, travel and our coordination services are separate. Any paid specialist review or coordination service is explained and agreed before you proceed.

Your next step

Start with your question

Tell us your diagnosis and what you need. Our free initial review checks the information and helps identify a suitable next step; it is not a specialist opinion or a hospital quotation.

Request a case-based estimate

Not ready to send records? Ask us first. Where hospital review is appropriate, we can help request an estimate. No travel commitment or mandatory proxy consultation.

Planning microbiota therapy in ChinaHospital review · individual costs · visit and follow-up

Plan the visit around the specific indication, treatment evidence and centre assessment. Agree the assessment route before travel.

Records for the microbiota therapy review

Tell us what you already have: C difficile toxin and stool-test results; Complete recurrence and antibiotic timeline; Hospital and infection-control records. Start with a short summary; after first contact we explain which records the receiving team needs and how to share them.

Confirm eligibility and access first

The assessment should establish whether the specific therapy, product or pathway is actually available to your case. The centre must confirm its criteria before an estimate or visit is agreed. Discuss: The indication and hospital eligibility review; The specific regulated pathway being considered; Screening, delivery and follow-up scope.

Visits and care after returning home

Ask which indication and regulated treatment pathway apply; availability and evidence for one use should not be assumed for another. Tell us if you need interpretation or English-language documents, and confirm the relevant arrangements with the receiving team.

Microbiota therapy transfers a screened microbial community for a defined indication

Fecal microbiota products or transplantation aim to restore gut microbial diversity, primarily after recurrent C. difficile infection has been treated with antibiotics.

Regulation and product availability differ between countries. Donor stool can transmit infection or other biological material, so informal or unscreened treatment is unsafe. Evidence for many marketed uses remains insufficient.

Ask exactly what product or donor pathway is used

The team should explain regulatory status, donor testing, manufacturing, route, storage, traceability and how serious adverse events are reported.

Who may be considered?

Specialist review may help when the diagnosis, symptoms and previous treatment create a focused question about microbiota-based therapy.

  • Adults with recurrent C. difficile infection after appropriate antibacterial treatment under local guidance.
  • Selected complex recurrent infection reviewed by infectious-disease and gastroenterology specialists.
  • A patient eligible for an approved microbiota product where available.
  • Research participants for other indications under formal ethics and safety oversight.

What the specialist team must confirm

Review includes confirmed toxin and symptom history, number and timing of recurrences, antibiotic courses, immune status, inflammatory bowel disease, pregnancy, severe food allergy, infection risk, current symptoms and whether diarrhea has another cause.

Key points for this treatment

Established roleselected recurrent C difficile infection
Formsapproved products or carefully governed FMT
Core safetydonor and pathogen screening
Not provengeneral detox obesity or routine IBD care
Chinese microbiology and gastroenterology team reviewing donor screening product traceability and antibiotic timing
Screening protects both patient and programmePathogen testing, donor eligibility, product release and storage controls are essential parts of treatment rather than administrative details.

From confirmed recurrence to controlled microbiota restoration

The team uses microbiota therapy only when indication, product quality and post-treatment monitoring are clear.

ConfirmVerify recurrent C difficile and exclusions
TreatComplete indicated antibacterial therapy
DeliverUse regulated product or governed donor pathway
MonitorTrack recurrence infection and adverse events

New symptoms require careful interpretation

Bloating, bowel-pattern change and other mild effects may occur, but fever, severe pain or recurrent diarrhea requires testing rather than assumption.

Avoid unnecessary antibiotics when possible while still treating genuine infections. Recurrence should be confirmed because other causes of diarrhea remain possible.

International patient discussing recurrence symptoms infection precautions and follow up after microbiota therapy
Traceability matters after treatmentPatients should retain product or donor batch information and the treating centre’s instructions for adverse-event reporting.
No recurrenceContinue symptom and safety monitoring
Diarrhea returnsRetest before retreatment
Adverse eventEvaluate infection and report appropriately
Unproven indicationUse research governance only

Risks, limits and realistic expectations

Microbiota products can transmit infectious agents and may cause abdominal symptoms or other unknown long-term effects. Effectiveness outside recurrent C. difficile prevention is uncertain and should not be overstated.

Do not delay urgent local care

High fever, severe abdominal pain, dehydration, confusion, blood in stool or rapidly worsening diarrhea after treatment requires urgent local assessment.

Before hospital review

Records for microbiota therapy assessment

A safe international review depends on dated source reports, original imaging and a complete treatment timeline—not a diagnosis label alone.

C difficile toxin and stool-test results
Complete recurrence and antibiotic timeline
Hospital and infection-control records
IBD and immune-status history
Exact product donor batch and route
Allergy pregnancy and medicine list
Procedure report and consent materials
Post-treatment symptoms and adverse-event plan
Continue reading

Related patient guides

Related guide

Inflammatory Bowel Disease Care

Explore the assessment and planning questions for this related care pathway.

Related guide

Gastrointestinal Bleeding Care

Explore the assessment and planning questions for this related care pathway.

Related guide

Gastroenterology

Explore the assessment and planning questions for this related care pathway.

Tell us what you need

Ask about your care,
your hospital and your budget.

You can ask about suitability, an expert opinion, an appointment or the likely medical cost. If you are unsure, choose “Not sure — please advise”.

This enquiry is aboutIntestinal Microbiota TherapyNot sure — please advise

How a personal estimate is prepared

  1. Tell us about your case.Describe your diagnosis, main question and preferred city, if any.
  2. Share the relevant records.We explain what is needed and how to send it by WhatsApp or email.
  3. Request a hospital estimate.Where appropriate, we help request hospital review and a cost estimate. Any paid review is agreed first.

This is an enquiry, not an order or payment. Proxy consultation is not mandatory. Any service scope is agreed separately before you proceed.

Ask about Intestinal Microbiota Therapy

A first enquiry is free. Email and permission to respond are required; the other details are optional. Any paid clinical review or coordination is discussed separately.

Included automatically so we know which procedure you are asking about.
A preference, not a confirmed appointment.
Please do not send passport numbers, card details or full medical files in this first enquiry. We will explain which records are needed next.

Send a short summary first. This is an enquiry, not an order, payment or confirmed appointment.

No booking or payment is made by sending this enquiry.
Editorial transparency

Medical sources

Patient information is based on established government and professional guidance. Content updated 5 October 2026. This is patient information, not an individual clinical assessment.